Arthur J. Gallagher has considerably underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.
Marsh & McLennan has considerably underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.
Aon plc has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.
As Aflac has underperformed the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.
While MetLife has underperformed the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Erie Indemnity has lagged behind other insurance peers over the past year, but analysts are reasonably upbeat about its prospects.
Despite Willis Towers Watson's outperformance relative to its industry peers over the past year, Wall Street analysts maintain a cautiously optimistic outlook on its prospects.
Although Arthur J. Gallagher’s performance has been mixed compare to its insurance peers, Wall Street remains upbeat about the stock’s longer-term prospects.
Willis Towers Watson draws market interest with innovative initiatives, outperforming industry peers. Despite trailing the broader market, analyst sentiment stays largely positive.
Arthur J. Gallagher stock has been underperforming the broader market over the past year, and analysts are adopting a cautiously bullish stance.